{"id":880002,"date":"2025-08-28T08:19:32","date_gmt":"2025-08-28T12:19:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/"},"modified":"2025-08-28T08:19:32","modified_gmt":"2025-08-28T12:19:32","slug":"cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/","title":{"rendered":"CytomX Therapeutics to Present at Upcoming September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Aug.  28, 2025  (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.<\/p>\n<p align=\"justify\">\n        <strong>Cantor Global Healthcare Conference 2025<\/strong><br \/>\n        <br \/>Date: Thursday, September 4, 2025<br \/>Fireside Chat: 8:35 a.m. ET<br \/>Location: New York, NY<\/p>\n<p align=\"justify\">\n        <strong>H.C. Wainwright 27<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Investment Conference<\/strong><br \/>\n        <br \/>Date: Tuesday, September 9, 2025<br \/>Formal Presentation: 11:30 a.m. ET<br \/>Location: New York, NY<\/p>\n<p align=\"justify\">\n        <strong>Morgan Stanley 23<\/strong><br \/>\n        <sup><br \/>\n          <strong>rd<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Healthcare Conference<\/strong><br \/>\n        <br \/>Date: Wednesday, September 10, 2025<br \/>Fireside Chat: 1:05 p.m. ET<br \/>Location: New York, NY<\/p>\n<p align=\"justify\">A live webcast of the presentation will be available on the Events and Presentations page of CytomX\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ldzNPaUVDWK_Jkjh4QMjpCruKo9qiFYTwHRut6LlcmLwMTgZFJUEy5xsipAg5_oHcpCNf1vghzOutz_vR7umXg==\" rel=\"nofollow\" target=\"_blank\">www.cytomx.com<\/a>. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0CytomX Therapeutics, Inc.<\/strong><br \/>\n        <br \/>CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY<sup>\u00ae<\/sup>\u00a0therapeutic platform, CytomX\u2019s vision is to create safer, more effective therapies for the treatment of cancer. CytomX\u2019s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX\u2019s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY<sup>\u00ae<\/sup>\u00a0cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas,\u00a0Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ldzNPaUVDWK_Jkjh4QMjpAI5E9prFqa6k8pgVVApXEID9ttmuM4RrOJ9hp3RphE_hAbuYTmmESGttCrA_LAHZa_eIM14qzNecujSxGBDsSttkOGWwbKStAOGIZBA8MaUqvU80Xamjvtst-RAuDk7Ye9Xs7a60MLYNU-_YlnSmFTgf8pQXAaiJtnPMyK4hWIytHGr-Au9X2bw9bDaVsE-bjXmKHAOIGP_wXQVsNRE6lMWYy2O3s4URk8ImSMJZzPGPd8QJVeYL-eiNbQ8cCiQf8Fq-fuAFHLzHGLadLnyFq3XZQPVL4vDu1VNTaGyYWUyL3Sr-8ngjKRTLTRGGe-TgxVN6JDuhbD-sDebTlU7HocXtw5uT_W6t7O3oq1FZ5b0J4jLRjIWEmF9Npjz-Opd2q-4iQk5qB2LxzpBRpxdw1s=\" rel=\"nofollow\" target=\"_blank\"><strong>www.cytomx.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IG7lm25PdioBB5RBulfWywhuOgZb6A8QK0OkjcR1Gq0KqB1KooT8O-SIO5QBKgClTahNuwtFCZyV_yUA9QiVlPz0rnZ0oCV6crX-XgtViK7dQvdWyUIxmKH2Z9Qgy9tjD6EZgQ4mFn8IFb_gC2rLv81gNLVwlx4bk6UHyT3gN0VOEglxM0ExxuEEfI7ah41DTsyFd6o7dRzuKBvgh7wgFBIORpUxXCVvGW3Mt9824zR_Qed_SVyXx0_3g_3LihyC0CVZXAqqqCEBlcIi4lKQH8mpvzt3pfE1FSM1WDwk2pRFa1MuUGurCEgC3qWya6oLVcDB8ui1IRw9opxOpROzXuHyS82KmINmebtjDTplKnGY3T4eM0H7flVK6B4zoG4pOXgbG-rm7UmSxhe5KcsUNZwWtklzhXjfESj2sSGDZqgLj0-dAbyyqkSnpHUU9t7USCsUGxHyyZZsDK4lNFIQD4002sxXIq0yu8QNbn3w4ok=\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PHni6-PcFq5zZbobQcQfKZ3VBmnXRPU1Od4NKnBCpsvnTij-umJsxUd5XFRLAnrCy_YECFXtlEV3wEH-U5QXtrJE_pleWWmD1OXJYURzdKThkbKGvmFDJS0q4RoFsnRElukkHR5HzdKZOw6vkPvHmO_d0L_IvT_sUQ8jLtcBhjGSNvpo5OiK0np3DqguWitm1sZJ_sbP5COO3HqpMVCw876WkZBVIkCzHFLEkkhLouNgstkXb2bWsjVyovQXitceV5IEbCob99_njdPbcxAjYNBt-6Mwm-rBX6E6l7Pzvyc14QmUUJHj0nwFYXcTNhTVbkIcS9GBFEg7qW_HTvjD9yKnnC4eUcBPwnqadGRaGAZDl6QXrxllBxSsH7CbKlOloi13e8nicz4f1IEbGEJXOvrIj0tOUOBFnbRh0iHgVD4ktq2arKLdJ6CIO6xmw_CU\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a>\u00a0(formerly Twitter).<\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Chris Ogden<br \/>SVP, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r9H2r-V577MM8-Ln51YRrqfa5x-MPZYctPKx3H8HZMYl7Bm-1HBinYV9_rNo9a5qBNitO03p-Lv7DRp6mG7lGKT0Tmby4SmWuD6Rjono0KQ=\" rel=\"nofollow\" target=\"_blank\">cogden@cytomx.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Precision AQ (formerly Stern Investor Relations)<br \/>Stephanie Ascher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7hrQJ0rZNR8EWhK-UjQ2WQRf8NOhfm5Wb_4ExS7OZ5igdJOl1R4z9uMVteL5QkCXiWMfWBqmxh_kmU8agxGcrVS5Rc6DjkGq7PxPm3NQ0MwhMxUW3DBB8YIRcyugGHrE\" rel=\"nofollow\" target=\"_blank\">stephanie.ascher@precisionaq.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Redhouse Communications<br \/>Teri Dahlman<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7j7_fkHzs0n28UNDO4wBoNYpLFGskJ1QR81-AZkHjYJiJkZGcsXdRAOWvAYAR2yZTZ7QBncNZZf8x8mDLkX23DmKCvY22jkzDCTKR3IrT70=\" rel=\"nofollow\" target=\"_blank\">teri@redhousecomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzFhMWMxNzgtMTc5OC00OTlmLWFmNGYtZGU5NTE4ZTNjYmY0LTEwMzE3OTktMjAyNS0wOC0yOC1lbg==\/tiny\/CytomX-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Cantor Global Healthcare Conference 2025 Date: Thursday, September 4, 2025Fireside Chat: 8:35 a.m. ETLocation: New York, NY H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9, 2025Formal Presentation: 11:30 a.m. ETLocation: New York, NY Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10, 2025Fireside Chat: 1:05 p.m. ETLocation: New York, NY A live webcast of the presentation will be available on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. In addition, management will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytomX Therapeutics to Present at Upcoming September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-880002","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytomX Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytomX Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Cantor Global Healthcare Conference 2025 Date: Thursday, September 4, 2025Fireside Chat: 8:35 a.m. ETLocation: New York, NY H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9, 2025Formal Presentation: 11:30 a.m. ETLocation: New York, NY Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10, 2025Fireside Chat: 1:05 p.m. ETLocation: New York, NY A live webcast of the presentation will be available on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. In addition, management will be &hellip; Continue reading &quot;CytomX Therapeutics to Present at Upcoming September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T12:19:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytomX Therapeutics to Present at Upcoming September Investor Conferences\",\"datePublished\":\"2025-08-28T12:19:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/\",\"name\":\"CytomX Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=\",\"datePublished\":\"2025-08-28T12:19:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytomX Therapeutics to Present at Upcoming September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytomX Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"CytomX Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) &#8212; CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Cantor Global Healthcare Conference 2025 Date: Thursday, September 4, 2025Fireside Chat: 8:35 a.m. ETLocation: New York, NY H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9, 2025Formal Presentation: 11:30 a.m. ETLocation: New York, NY Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10, 2025Fireside Chat: 1:05 p.m. ETLocation: New York, NY A live webcast of the presentation will be available on the Events and Presentations page of CytomX\u2019s website at www.cytomx.com. In addition, management will be &hellip; Continue reading \"CytomX Therapeutics to Present at Upcoming September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-28T12:19:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytomX Therapeutics to Present at Upcoming September Investor Conferences","datePublished":"2025-08-28T12:19:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/","name":"CytomX Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=","datePublished":"2025-08-28T12:19:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxNjQ5OCM3MTEwOTY5IzIwMjAyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytomx-therapeutics-to-present-at-upcoming-september-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytomX Therapeutics to Present at Upcoming September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=880002"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880002\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=880002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=880002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=880002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}